Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 + Cetrelimab vs Chemoradiotherapy in Muscle-Invasive Bladder Cancer
NCT04658862Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Device-based Delivery, Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised trial of gemcitabine-releasing intravesical system and cetrelimab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Bladder Intact Event-free Survival at 8 years. Started Dec 2020; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04658862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658862.